Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity (2013 - 2025)

Larimar Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $145.8 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 27.16% year-over-year to $145.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $653.4 million (down 27.78% YoY) and the FY2025 annual result came in at $145.8 million, down 27.16% from the prior year.
• Liabilities and Shareholders Equity was $145.8 million for Q4 2025 at Larimar Therapeutics, down from $187.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $248.2 million in Q1 2024 and bottomed at $62.9 million in Q2 2022.
• A 5-year average of $136.1 million and a median of $122.7 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 1726.33% — and 2025, when it sank 36.76%.
• Larimar Therapeutics' Liabilities and Shareholders Equity stood at $78.7 million in 2021, then surged by 60.68% to $126.4 million in 2022, then dropped by 24.11% to $95.9 million in 2023, then jumped by 108.71% to $200.2 million in 2024, then decreased by 27.16% to $145.8 million in 2025.
• Business Quant data shows LRMR's Liabilities and Shareholders Equity at $145.8 million in Q4 2025, $187.4 million in Q3 2025, and $150.0 million in Q2 2025.